These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2631736)

  • 1. Synergism between ciprofloxacin and fosfomycin against gram-negative bacteria in vitro.
    Vogt K; Hahn H
    Zentralbl Bakteriol; 1989 Dec; 272(2):225-30. PubMed ID: 2631736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of fosfomycin against 'problem' gram-positive cocci.
    Hamilton-Miller JM
    Microbios; 1992; 71(287):95-103. PubMed ID: 1453987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas isolates from patients with cystic fibrosis.
    Figueredo VM; Neu HC
    J Antimicrob Chemother; 1988 Jul; 22(1):41-50. PubMed ID: 3139615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro activity of fosfomycin, alone or in combination, against clinical isolates of carbapenem resistant Pseudomonas aeruginosa].
    Gómez-Garcés JL; Gil-Romero Y; Sanz-Rodríguez N; Muñoz-Paraíso C; Regodón-Domínguez M
    Enferm Infecc Microbiol Clin; 2016 Apr; 34(4):228-31. PubMed ID: 26277206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.
    Demir T; Buyukguclu T
    Int J Infect Dis; 2013 Nov; 17(11):e966-70. PubMed ID: 23742831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergism of trimethoprim and ciprofloxacin in vitro against clinical bacterial isolates.
    Huovinen P; Wolfson JS; Hooper DC
    Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):255-7. PubMed ID: 1597204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.
    Tessier F; Quentin C
    Eur J Clin Microbiol Infect Dis; 1997 Feb; 16(2):159-62. PubMed ID: 9105845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study.
    Fajfr M; Louda M; Paterová P; Ryšková L; Pacovský J; Košina J; Žemličková H; Broďák M
    BMC Urol; 2017 Apr; 17(1):33. PubMed ID: 28446177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fosfomycin.
    Falagas ME; Vouloumanou EK; Samonis G; Vardakas KZ
    Clin Microbiol Rev; 2016 Apr; 29(2):321-47. PubMed ID: 26960938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
    Walsh CC; Landersdorfer CB; McIntosh MP; Peleg AY; Hirsch EB; Kirkpatrick CM; Bergen PJ
    J Antimicrob Chemother; 2016 Aug; 71(8):2218-29. PubMed ID: 27118778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of ciprofloxacin in its synergistic effect with fosfomycin on drug-resistant strains of Pseudomonas aeruginosa.
    Yamada S; Hyo Y; Ohmori S; Ohuchi M
    Chemotherapy; 2007; 53(3):202-9. PubMed ID: 17356268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergy of fosfomycin with beta-lactam antibiotics against staphylococci and aerobic gram-negative bacilli.
    Chin NX; Neu NM; Neu HC
    Drugs Exp Clin Res; 1986; 12(12):943-7. PubMed ID: 3569007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials.
    Samonis G; Maraki S; Rafailidis PI; Kapaskelis A; Kastoris AC; Falagas ME
    Future Microbiol; 2010 Jun; 5(6):961-70. PubMed ID: 20521939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.
    Ko KS; Suh JY; Peck KR; Lee MY; Oh WS; Kwon KT; Jung DS; Lee NY; Song JH
    Diagn Microbiol Infect Dis; 2007 May; 58(1):111-5. PubMed ID: 17300900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of doripenem plus fosfomycin against drug-resistant clinical blood isolates.
    Lingscheid T; Tobudic S; Poeppl W; Mitteregger D; Burgmann H
    Pharmacology; 2013; 91(3-4):214-8. PubMed ID: 23548688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro activity and synergism of fosfomycin and cefotaxime.
    Carvajal A
    J Antimicrob Chemother; 1985 Nov; 16(5):677. PubMed ID: 4077775
    [No Abstract]   [Full Text] [Related]  

  • 17. Synergism between ciprofloxacin and fosfomycin in vitro.
    Ullmann U
    Infection; 1987; 15(4):264. PubMed ID: 3117699
    [No Abstract]   [Full Text] [Related]  

  • 18. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies.
    Falagas ME; Kastoris AC; Karageorgopoulos DE; Rafailidis PI
    Int J Antimicrob Agents; 2009 Aug; 34(2):111-20. PubMed ID: 19403273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments.
    Albur MS; Noel A; Bowker K; MacGowan A
    Int J Antimicrob Agents; 2015 Nov; 46(5):560-7. PubMed ID: 26387065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Synergic action of the combination of fosfomycin and kanendomycin against gram-positive and gram-negative bacteria].
    Russo G; Toscano MA; Gismondo MR; Nicolosi V; Garaci E
    Ann Sclavo; 1980; 22(1):77-82. PubMed ID: 7247487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.